A-shares open · 港股交易中 Quotes 行情 · 28 Sep 14:11 CST
28 Sep 2026 · 14:11 CST Terminal Access 终端入口 →
600222.SH上海证券交易所 · 主板 Main

Taloph 太龙药业

Traditional Chinese Medicine 中药Ⅱ
¥8.04+¥0.01 · +0.12%Live 实时 · 28 Sep 2026 · 14:10 CST · CNY
Open 开盘
¥8.09
High 最高
¥8.16
Low 最低
¥7.87
Prev Close 昨收
¥8.03
Volume 成交量
1,253.0万股
Turnover 成交额
¥9,996.8万
Mkt Cap 总市值
¥45亿
P/E 市盈率
85.4×
Recent Activity 近期动态All Filings 全部公告 →

8 significant filings since 31 May 2026: 2 on shares frozen, 2 on legal representative change and 1 on new listing, and 3 other kinds. The latest, on 10 Sep 2026: 太龙药业关于持股5%以上股东股份被轮候冻结的公告.
自 31 May 2026 起有 8 份重大公告:shares frozen 2 份、legal representative change 2 份、new listing 1 份,另有 3 类。最新一份(10 Sep 2026):太龙药业关于持股5%以上股东股份被轮候冻结的公告。

Price History 价格走势

1,250 trading days 个交易日 · High 最高 ¥10.05 · Low 最低 ¥3.90
4.005.006.007.008.009.0010.00
Volume 成交量
1.71亿
20212022202420252026

Against Its Own History 与自身历史比较

85.4×
Median 中值 71.6× · Range 区间 21.8× to 839.3× · 13 periods 期
2.86×
Median 中值 2.22× · Range 区间 1.55× to 3.10× · 20 periods 期

Period by Period 逐期

Period 报告期Close at Period End 期末收盘TTM EPS 滚动每股收益 BPS 每股净资产
30 Jun 2026 中报¥7.26¥0.1076.2×¥2.812.58×
31 Mar 2026 一季报¥7.07¥0.1164.0×¥2.802.53×
31 Dec 2025 年报¥6.58¥0.1160.6×¥2.802.35×
30 Sep 2025 三季报¥6.49¥0.0876.6×¥2.782.34×
30 Jun 2025 中报¥5.59¥0.0871.6×¥2.792.00×
31 Mar 2025 一季报¥5.25¥0.0694.6×¥2.751.91×
31 Dec 2024 年报¥5.09¥0.0956.1×¥2.741.85×
30 Sep 2024 三季报¥5.28¥0.1633.1×¥2.741.93×
30 Jun 2024 中报¥4.20¥0.1921.8×¥2.701.55×
31 Mar 2024 一季报¥5.28¥0.1148.4×¥2.761.91×
31 Dec 2023 年报¥6.13¥0.0879.2×¥2.752.23×
30 Sep 2023 三季报¥5.59−¥0.06—¥2.532.21×
30 Jun 2023 中报¥5.88−¥0.15—¥2.472.38×
31 Mar 2023 一季报¥5.87−¥0.13—¥2.712.17×
31 Dec 2022 年报¥6.37−¥0.13—¥2.742.33×
30 Sep 2022 三季报¥5.23−¥0.14—¥2.731.92×
30 Jun 2022 中报¥5.89−¥0.08—¥2.892.04×
31 Mar 2022 一季报¥8.00−¥0.03—¥3.042.63×
31 Dec 2021 年报¥8.98¥0.01839.3×¥2.893.10×
30 Sep 2021 三季报¥8.35¥0.06144.5×¥2.832.96×

Consensus Forward EPS 机构预测每股收益

No broker forecasts for this company yet 暂无机构预测

Not Computed 未计算
  • Dividend Yield 股息率
  • Free Cash Flow 自由现金流
  • EV/EBITDA